Walleye Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Walleye Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-75,000	Closed	-$1.79M	–	2020
2019 Q4	$1.79M	Buy	+75,000	New	+$2.07M	0.12%	232
2019 Q3	–	Sell	-5,000	Closed	-$136K	–	2427
2019 Q2	$136K	Sell	5,000 -5,500	-52%	-$172K	0.01%	1118
2019 Q1	$364K	Buy	+10,500	New	+$303K	0.06%	514

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Walleye Capital's PTLA Position: Q2 2020 in Review

Walleye Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 67,327 shares — an estimated $481K sold.

Walleye Capital first reported a position in PTLA in Q1 2019 and held it in 3 quarters. The position peaked at $997K in Q4 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Walleye Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Walleye Capital sold 67,327 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $481K.
Walleye Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 3 quarters.
Walleye Capital's Portola Pharmaceuticals, Inc. position peaked at $997K in Q4 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Walleye Capital's 13F filing for Q2 2020, filed 14 Aug 2020.